The price disparity between the two drugs will only increase in 2006, when Pravachol loses patent protection. (Lipitor does not lose patent protection until 2010.) At that point, cheap generic Pravachol copycats are likely to flood the market.
In each instance, Gray pushes a generic situation to an expressionistic crisis point -- and Bobby forfeits another ounce of his humanity.
Obama has only a seven-point lead over a generic Republican among young voters, according to an April survey conducted by the Public Religion Research Institute and Georgetown University.
The antidepressant's patent runs out on Aug. 2, at which point you can bet generic drugmaker Barr Laboratories (nyse: BRL - news - people) of Pomona, N.
Democratic congressional candidates have a 9-point lead in the 'generic ballot' question.
While they were at no point bad, Halo 3 was somewhat generic and predictable through a lot of the storyline and ODST was a downloadable expansion gone large.
Morningstar pharmaceutical-industry analyst Damien Conover estimates that Pfizer can expect generic competition to undercut gains from new drugs, to the point that sales will grow by just 1% a year on average going forward.
The beauty of this, at least from big pharma's point of view, is that when companies sued generic-drug makers and lost, they still kept copycats off the market for several months--and that often meant hundreds of millions of dollars in sales.
But critics would say Vioxx's problems started in 2001, two years before Kim fully took over as head of Merck research. (He had just left a job as a biologist at the Massachusetts Institute of Technology.) A U.S. Food and Drug Administration advisory panel was reviewing a large study that proved Vioxx's big selling point: it causes fewer ulcers than cheaper, generic pain pills.
Into July 2009, Apotex continued to press Watson for a deal, indicating at one point through an email that Apotex had previously been in touch with FTC about generic Provigil.
FORBES: One Federal Agency��s Crusade Against Patent Litigation Settlements
The main point of the article is to explain why FDA is not taking action against Spiriva (generic name: tiotropium), a treatment for chronic obstructive pulmonary disorder sold by Boehringer Ingelheim and Pfizer, despite a meta-analysis that raised concerns.
应用推荐